Suppression of BACE1 and amyloidogenic/RAGE axis by sitagliptin ameliorates PTZ kindling-induced cognitive deficits in rats

Chem Biol Interact. 2020 Sep 1:328:109144. doi: 10.1016/j.cbi.2020.109144. Epub 2020 Jul 9.

Abstract

The debilitating nature of cognitive impairment in epilepsy and the potential of some traditional antiepileptics to further deteriorate cognitive function are areas of growing concern. Glucagon-like peptide-1 (GLP-1) deficiency has been linked to reduced seizure threshold as well as cognitive dysfunction. Here, we tested whether sitagliptin (SITA), by virtue of its neuroprotective properties, could alleviate both epilepsy and associated cognitive dysfunction in a rat model of kindling epilepsy. Chemical kindling was induced by subconvulsive doses of pentylenetetrazol (PTZ) (30 mg/kg; i.p). SITA (50 mg/kg; p.o) was administered 1 h before PTZ injections. SITA conceivably attenuated PTZ hippocampal histological insult, preserved neuronal integrity and amended neurotransmitter perturbations in rat hippocampi paralleled with enhanced hippocampal GLP-1 levels as well as the downstream cAMP content and protein kinase A (PKA) activity. Moreover, SITA improved cognitive functioning of rats in the Morris water maze which was coupled with hampered hippocampal p(Ser404)-tau and β-amyloid proteins. SITA replenished p(Ser9)-glycogen synthase kinase-3β (GSK-3β). It also opposed the boosted matrix metalloproteinase-9 (MMP-9), brain-derived neurotrophic factor (BDNF), and insulin-like growth factor-1 (IGF-1) levels associated with PTZ administration along with mitigation of both β-secretase-1 (BACE1) immunoreactivity and receptor for advanced glycation end products (RAGE) protein level in rat hippocampi. In conclusion, SITA subdues epileptic and cognitive upshots of PTZ kindling in rats, which might correspond to the modulation of BACE1, amyloidogenic/RAGE axis as well as GSK-3β/MMP-9/BDNF signaling cascade. SITA effects are probably mediated via boosting GLP-1 and subsequently enhancing GLP-1/GLP-1R signaling.

Keywords: BDNF; DPP-4; GLP-1; Morris water maze; Seizures; β-amyloid.

MeSH terms

  • Amyloid / metabolism*
  • Amyloid Precursor Protein Secretases / metabolism*
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Aspartic Acid Endopeptidases / metabolism*
  • Biomarkers / metabolism
  • Brain-Derived Neurotrophic Factor / metabolism
  • Cognition Disorders / chemically induced*
  • Cognition Disorders / metabolism*
  • Cognition Disorders / pathology
  • Glucagon-Like Peptide 1 / metabolism
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Hippocampus / drug effects
  • Hippocampus / pathology
  • Insulin-Like Growth Factor I / metabolism
  • Kindling, Neurologic / drug effects*
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Neural Inhibition / drug effects
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / pathology
  • Neurotransmitter Agents / metabolism
  • Pentylenetetrazole
  • Rats, Wistar
  • Receptor for Advanced Glycation End Products / metabolism*
  • Seizures / chemically induced
  • Seizures / metabolism
  • Seizures / pathology
  • Signal Transduction* / drug effects
  • Sitagliptin Phosphate / pharmacology*
  • Spatial Memory / drug effects
  • tau Proteins / metabolism

Substances

  • Amyloid
  • Amyloid beta-Peptides
  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • Neurotransmitter Agents
  • Receptor for Advanced Glycation End Products
  • tau Proteins
  • Insulin-Like Growth Factor I
  • Glucagon-Like Peptide 1
  • Glycogen Synthase Kinase 3 beta
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases
  • Bace1 protein, rat
  • Matrix Metalloproteinase 9
  • Sitagliptin Phosphate
  • Pentylenetetrazole